Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash from Operations (2018 - 2025)

Zevra Therapeutics' Cash from Operations history spans 11 years, with the latest figure at 5516000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 133.94% year-over-year to 5516000.0; the TTM value through Dec 2025 reached 1598000.0, up 97.71%, while the annual FY2025 figure was 1598000.0, 97.71% up from the prior year.
  • Cash from Operations reached 5516000.0 in Q4 2025 per ZVRA's latest filing, up from 4709000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 16603000.0 in Q2 2021 to a low of 19109000.0 in Q2 2024.
  • Average Cash from Operations over 5 years is 5653800.0, with a median of 4283000.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: skyrocketed 657.09% in 2021, then plummeted 426.18% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 848000.0 in 2021, then tumbled by 426.18% to 4462000.0 in 2022, then plummeted by 262.12% to 16158000.0 in 2023, then fell by 0.57% to 16250000.0 in 2024, then surged by 133.94% to 5516000.0 in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Cash from Operations are 5516000.0 (Q4 2025), 4709000.0 (Q3 2025), and 3601000.0 (Q2 2025).